Medicinova's 2025 10-K Reveals $0.41M Revenue, $(0.24) EPS Amidst $80M Capital Access Initiatives
MNOV sits 25% above its 52-week low of $1.13 on light trading volume (0.2× avg).
Summary
Medicinova reported its 2025 annual financial results from its 10-K filing, showing $0.41 million in revenue and a net loss per share of $(0.24). The company recorded a net loss of $(12.00) million and an operating loss of $(13.28) million, reflecting continued investment in R&D. This news provides specific financial details from the 10-K filing that was made earlier today, which the timeline indicated also highlighted clinical trial progress and new equity financing programs. The company has secured new capital access measures, including a $30 million structured equity purchase agreement and a $50 million at-the-market facility, to support ongoing development. For a company of Medicinova's size, these annual results and financing efforts are material, providing a projected 12-month cash runway. Investors will monitor the progress of clinical trials and the utilization of these financing facilities.
At the time of this announcement, MNOV was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69.3M. The 52-week trading range was $1.13 to $1.96. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.